August 3, 2023: FDA greenlights light-activated device for use in vascular disease trial.

Medical Device Record. A drug-coated balloon that helps restore blood vessels via light activation has been approved for use in US clinical trials. Read Article

January 9, 2023: First Patient Enrolled in the First-in-Human Clinical Trial of Novel AlucentNVS Technology

Alucent Biomedical Announces First Patient Enrolled in the First-in-Human Clinical Trial of Its Novel AlucentNVS Technology for Arteriovenous Fistula (AVF) in People with End Stage Renal Disease (ESRD) Press Release

April 2022: Alucent Biomedical Announces First Patient

First Patient Enrolled in First in Human Natural Vascular Scaffolding Clinical Trial Press Release

January 2021: Frontiers in Bioengineering & Biotechnology

Natural Vascular Scafolding Treatment PromotesOutward Remodeling during Arteriovenous Fistula Development in Rats. Read Article

January 2021: MedTech Strategist

Alucent Biomedical Re-Envisioning PAD Treatment with a Natural Vascular Scaffold. Read Article

December 2020

Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market Press Release

October 2020: Vascular Cures

Innovation spotlight – “Can We Make Stents Obsolete?” Read Article

October 2020

Alucent Biomedical Announces $35 Million Series B Financing Press Release

May 2020

Alucent Biomedical Announces First Patient Enrolled in Phase 1 Natural Vascular Scaffolding Clinical Trial Press Release

January 2020

Alucent Biomedical Announces FDA Approval to Proceed with Natural Vascular Scaffolding Clinical Trial Press Release

September 2018

Alucent Biomedical Announces Formation of Scientific Advisory Board Press Release

Alucent Biomedical

Corporate Fact Sheet View

NVS Restoration System Fact Sheet

The Alucent NVS Vessel Restoration System with Photoactivated Linking View

Alucent NVS Procedure Animation

Short video illustrating the NVS procedure View